Fight CRC Clinical Trial Finder
NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
---|---|---|---|---|---|---|---|---|---|
NCT ID NCT05438342 |
TitleAn Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis | Phase
Not Applicable
|
Date Added 2022-06-29 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
Chemotherapy,checkpoint immunotherapy, targeted therapy |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT05611034 |
TitleIn Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung | Phase
Phase 1
|
Date Added 2022-11-09 |
Location
Canada
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
oxaliplatin |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT05479812 |
TitleDose Escalation Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors | Phase
Phase 1
|
Date Added 2022-07-29 |
Location
Arizona, United States
Florida, United States Georgia, United States Illinois, United States Indiana, United States New Jersey, United States New York, United States Oregon, United States Texas, United States |
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
Pembrolizumab, WTX-124 |
Tags
MSI-H/ MMRd
|
NCT ID NCT05487235 |
TitleA Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Phase
Phase 1
|
Date Added 2022-08-04 |
Location
Argentina
Australia Brazil Canada Korea, Republic of New Zealand |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Atezolizumab, GDC-1971, Omeprazole |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT05491317 |
TitleA Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a Treatment Option for Subjects With Metastatic Solid Tumors | Phase
Phase 1, Phase 2
|
Date Added 2022-08-08 |
Location
France
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Pembrolizumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT05493683 |
TitleDisitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer | Phase
Phase 2
|
Date Added 2022-08-09 |
Location
China,China,China,China,China,China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Disitamab vedotin, Tislelizumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT04262687 |
TitleChemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate | Phase
Phase 2
|
Date Added 2020-02-10 |
Location
France
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Bevacizumab, capecitabine, oxaliplatin, Pembrolizumab |
Tags
MSS/ MMRp
|
NCT ID NCT05205330 |
TitleA Phase Ib/IIa Study of CR6086 in Combination With Balstilimab in pMMR-MSS Metastatic Colorectal Cancer Patients | Phase
Phase 2
|
Date Added 2022-01-25 |
Location
Italy
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
AGEN2034, Balstilimab, CR6086 |
Tags
MSS/ MMRp
|
NCT ID NCT05201612 |
TitlePembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC). | Phase
Phase 2
|
Date Added 2022-01-21 |
Location
Spain
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Unknown status
|
Drugs
Olaparib, Pembrolizumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
NCT ID NCT03104439 |
TitleNivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer | Phase
Phase 2
|
Date Added 2017-04-07 |
Location
Massachusetts, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Ipilimumab, Nivolumab, Opdivo, Yervoy |
Tags
MSI-H/ MMRd, MSS/ MMRp
|